Barbero Luca M, Ianni Andrea Di, Molinaro Francesco, Cowan Kyra J, Sirtori Federico Riccardi
NBE-DMPK Innovative BioAnalytics, Merck Serono RBM S.P.A., An Affiliate of Merck KGaA, Darmstadt, Germany, Via Ribes 1, Colleretto Giacosa (TO) 10010, Italy.
NBE-DMPK Innovative BioAnalytics, Merck Serono RBM S.P.A., An Affiliate of Merck KGaA, Darmstadt, Germany, Via Ribes 1, Colleretto Giacosa (TO) 10010, Italy; Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin 10126, Italy.
Eur J Pharm Sci. 2023 Sep 1;188:106502. doi: 10.1016/j.ejps.2023.106502. Epub 2023 Jun 17.
Preclinical in vivo and in vitro characterization of Antibody-Drug Conjugates (ADCs) involves the development of several bioanalytical methods to address many drug exposure questions. The current pharma industry approach requires at least three different assays that must be run, i.e., total antibody (mAb), conjugated payload or conjugated mAb, and free payload assays. Herein we present analytical performances of a quantitative hybrid Ligand Binding/Liquid Chromatography High Resolution and Accuracy Mass Spectrometry (LB/LCHRAM) method that can condense much of the necessary bioanalytical information in one method. The method includes an immuno-capture step, and it detects whole ADC molecules. It was applied to plasma mouse samples and showed reliable bioanalytical performance according to full method validation standards. Quantitation using extracted ion chromatograms and deconvoluted mass peaks was evaluated. The limit of quantitation resulted in 0.5ng of protein on column with a linear dynamic range spanning from 0.5 to 10μg/mL. Moreover, lower drug-to-antibody ratio (DAR) ADC species can be simultaneously detected, also enabling qualitative characterization of in vivo ADC conjugation.
抗体药物偶联物(ADC)的临床前体内和体外特性研究涉及开发多种生物分析方法,以解决诸多药物暴露问题。当前制药行业的方法需要至少进行三种不同的检测,即总抗体(单克隆抗体)、偶联的有效载荷或偶联的单克隆抗体以及游离有效载荷检测。在此,我们展示了一种定量混合配体结合/液相色谱高分辨率和精确质量质谱(LB/LCHRAM)方法的分析性能,该方法能够在一种方法中浓缩许多必要的生物分析信息。该方法包括一个免疫捕获步骤,可检测完整的ADC分子。它应用于小鼠血浆样本,并根据完整的方法验证标准显示出可靠的生物分析性能。评估了使用提取离子色谱图和去卷积质量峰进行定量的情况。定量限为柱上0.5 ng蛋白质,线性动态范围为0.5至10μg/mL。此外,较低药物与抗体比率(DAR)的ADC种类能够同时被检测到,这也使得能够对体内ADC偶联进行定性表征。